AU2024259627A1 - Methods of treating hepatic-only metastatic uveal melanoma - Google Patents

Methods of treating hepatic-only metastatic uveal melanoma

Info

Publication number
AU2024259627A1
AU2024259627A1 AU2024259627A AU2024259627A AU2024259627A1 AU 2024259627 A1 AU2024259627 A1 AU 2024259627A1 AU 2024259627 A AU2024259627 A AU 2024259627A AU 2024259627 A AU2024259627 A AU 2024259627A AU 2024259627 A1 AU2024259627 A1 AU 2024259627A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024259627A
Other languages
English (en)
Inventor
Yujiro Hata
Matthew Anthony MAURER
Michael Gabriel O'QUIGLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Ideaya Biosciences Inc
Original Assignee
Pfizer Inc
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, Ideaya Biosciences Inc filed Critical Pfizer Inc
Publication of AU2024259627A1 publication Critical patent/AU2024259627A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2024259627A 2023-04-21 2024-04-19 Methods of treating hepatic-only metastatic uveal melanoma Pending AU2024259627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363497590P 2023-04-21 2023-04-21
US63/497,590 2023-04-21
PCT/US2024/025461 WO2024220839A1 (en) 2023-04-21 2024-04-19 Methods of treating hepatic-only metastatic uveal melanoma

Publications (1)

Publication Number Publication Date
AU2024259627A1 true AU2024259627A1 (en) 2025-11-06

Family

ID=93153246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024259627A Pending AU2024259627A1 (en) 2023-04-21 2024-04-19 Methods of treating hepatic-only metastatic uveal melanoma

Country Status (6)

Country Link
EP (1) EP4698282A1 (he)
KR (1) KR20260005936A (he)
AU (1) AU2024259627A1 (he)
IL (1) IL324041A (he)
MX (1) MX2025012553A (he)
WO (1) WO2024220839A1 (he)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060781A1 (en) * 2017-09-22 2019-03-28 Washington University TARGETED PHARMACOLOGICAL THERAPEUTIC AGENTS IN UREAL MELANOMA
US11679113B2 (en) * 2019-04-11 2023-06-20 The Regents Of The University Of California Anticancer treatment for uveal melanoma
US20230152322A1 (en) * 2020-01-31 2023-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating uveal melanoma
WO2022055893A1 (en) * 2020-09-08 2022-03-17 Ideaya Biosciences Inc. Pharmaceutical combination and tumor treatment

Also Published As

Publication number Publication date
EP4698282A1 (en) 2026-02-25
MX2025012553A (es) 2026-01-07
WO2024220839A1 (en) 2024-10-24
KR20260005936A (ko) 2026-01-12
IL324041A (he) 2025-12-01

Similar Documents

Publication Publication Date Title
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
US20250090514A1 (en) Method of treating cancer
US20240207257A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
TW202133857A (zh) 用於乳癌治療之組合療法
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US20230040125A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
WO2024220839A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
EP4665325A1 (en) Compositions and methods of using eflornithine
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
WO2023175477A1 (en) Treatment of breast cancer with amcenestrant
KR20230044452A (ko) 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물
EP2968289A1 (en) 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma
TW202029961A (zh) Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途
EP4085908A1 (en) Pharmaceutical combination for treating tumors and application thereof
WO2024044775A1 (en) Methods of treating uveal melanoma
US20260083731A1 (en) Methods of treating uveal melanoma with a pkc inhibitor
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
CA3227813A1 (en) Pharmaceutical composition for treating solid tumors
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂